Nucleic acid-based regulation of the motor endplate
By using nucleic acid molecules and vectors that encode motor endplate receptors, targeted expression of neuromuscular transmission was achieved, solving the problems of systemic toxicity and immunogenicity in neurotoxin therapy and providing sustained and precise therapeutic effects.
Patent Information
- Application Number
- CN202580015768.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-20
- Filing Date
- 2025-02-20
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, treatment strategies for neurotoxins such as BoNT and TeNT rely on repeated injections, leading to systemic toxicity, immunogenicity, and frequent administration, making it difficult to achieve sustained and targeted neuromuscular inhibition, and posing a risk of side effects due to overdose.
By using nucleic acid molecules that encode motor endplate receptors or fragments thereof, particularly acetylcholine receptors (AChR) and muscle-specific receptor tyrosine kinases (MuSK), and combining nucleic acid vectors and fusion proteins, targeted expression and precise control of neuromuscular transmission can be achieved, reducing systemic side effects.
It achieves precise regulation of neuromuscular transmission, reduces systemic toxicity and immune response, prolongs the therapeutic effect, reduces the need for frequent dosing, and improves the specificity and safety of the treatment.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the fields of biotechnology and gene therapy, particularly to gene therapy, neuromuscular modulation, and recombinant protein expression.
[0002] This invention relates to nucleic acid molecules for regulating neuromuscular transmission, the nucleic acid molecules containing sequences encoding one or more receptors or fragments thereof for motor endplates.
[0003] The present invention also relates to nucleic acid vectors comprising nucleic acid molecules according to the present invention, wherein the vector is a viral vector, such as a lentiviral vector or a retroviral vector, a transposon, an RNA vector, or nanoparticles, such as lipid nanoparticles, liposomes, or polyethyleneimine (PEI).
[0004] This invention relates to fusion proteins, preferably comprising one or more of the features of any one or more of the preceding claims, wherein the fusion protein comprises a receptor for the motor endplate and / or a fragment thereof, wherein the receptor for the motor endplate is an acetylcholine receptor (AChR), a muscle-specific receptor tyrosine kinase (MuSK), and / or a glutamate receptor and / or a fragment thereof, and / or a neurotoxin, wherein the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin.
[0005] This invention relates to an in vitro method for regulating neuromuscular transmission, which includes transfecting eukaryotic cells with the nucleic acid molecules of this invention.
[0006] This invention relates to cells comprising genetically modified nucleic acid molecules, vectors, or fusion proteins according to the present invention. Background Technology
[0007] Neurotoxins are a class of bioactive molecules that disrupt neuronal signaling by targeting key components of synaptic transmission. Among them, botulinum toxin (BoNT) and tetanus toxin (TeNT) are structure-associated clostridium neurotoxins that exert their effects through the proteolytic cleavage of SNARE proteins, essential for synaptic vesicle fusion and neurotransmitter release. While BoNT primarily inhibits acetylcholine release at the neuromuscular junction, inducing local muscle paralysis, TeNT is retrogradely transported within motor neurons to the central nervous system, where it blocks inhibitory neurotransmission, leading to spastic paralysis. Despite their shared SNARE protein cleavage mechanism, their functional outcomes differ significantly: BoNT has been widely used in therapeutic applications, including the treatment of spasticity, dystonia, hyperhidrosis, and cosmetic medicine, while TeNT remains primarily associated with the pathological condition of tetanus infection. The therapeutic efficacy of BoNT stems from its ability to transiently inhibit presynaptic neurotransmitter release at the motor endplate, thereby causing muscle paralysis. This is achieved through the cleavage of the SNARE protein, which prevents synaptic vesicle fusion and acetylcholine release, thereby inactivating the acetylcholine receptor (AChR) at the neuromuscular junction and inhibiting muscle contraction.
[0008] Receptors at the motor endplate play a fundamental role in neuromuscular transmission by mediating the conversion of neuronal signals into muscle activation. These receptors are located within the postsynaptic membrane of the neuromuscular junction, where they regulate synaptic signal transduction and ensure precise muscle control.
[0009] Nicotinic acetylcholine receptors (AChRs) are transmembrane receptors expressed in neurons and muscle cells, facilitating synaptic transmission of impulses from motor neurons to muscle fibers. Activation of the AChR requires the binding of two acetylcholine (ACh) molecules, opening its ion channel, and subsequently depolarizing the muscle cell membrane. Structurally, the AChR contains five subunits, the composition of which varies between developmental stages. The fetal isotype consists of two α1, one β1, one γ, and one δ subunit, while the adult isotype uses the ε subunit instead of the γ subunit. The fetal isotype exhibits a uniform distribution throughout the myofascitis membrane, while the adult isotype is concentrated at the neuromuscular junction.
[0010] Muscle-specific receptor tyrosine kinase (MuSK) plays a crucial role in synapse formation and maintenance at the neuromuscular junction. MuSK comprises three extracellular immunoglobulin-like (Ig-like) domains, a cysteine-rich coil-like domain, and an intracellular tyrosine kinase domain, all of which are essential for neuromuscular signal transduction and synaptic integrity.
[0011] Neurotoxins such as BoNT and TeNT disrupt this finely regulated system by targeting the presynaptic release of neurotransmitters. BoNT inhibits the release of acetylcholine at the neuromuscular junction, leading to localized muscle paralysis, which is used therapeutically for conditions such as spasticity and dystonia. In contrast, TeNT is retrogradely transported to the central nervous system, where it blocks inhibitory neurotransmission, resulting in uncontrolled muscle contractions and spastic paralysis.
[0012] Given the current technology, an unmet need is to develop methods that can achieve prolonged and localized BoNT-mediated neuromuscular inhibition while minimizing systemic toxicity, immunogenicity, and the need for frequent dosing. Current treatment strategies rely on repeated BoNT injections, which are associated with dose-dependent diffusion beyond the intended site of action, increasing the risk of adverse effects and reducing therapeutic efficacy over time. Furthermore, repeated exposure to BoNT can lead to the development of immune resistance, limiting its long-term therapeutic potential. Therefore, there is an urgent need for an improved approach to ensure sustained, targeted delivery of BoNT or related neurotoxic agents, thereby enhancing therapeutic efficacy, reducing patient burden, and mitigating systemic side effects. Summary of the Invention
[0013] Given the prior art, a potential technical problem of the present invention is to provide alternative or improved means for methods used to modulate neuromuscular transmission at the motor endplate. The present invention seeks to provide such means while avoiding the known disadvantages of the prior art.
[0014] Another object of the present invention is to provide alternative or improved means to mitigate the risk of overdose associated with long-term or overexpression of neurotoxins, which may lead to systemic side effects.
[0015] Another object of the present invention is to provide alternative or improved means for making specific local modifications to synaptic function at the site of action.
[0016] Another object of the present invention is to provide alternative or improved means for reducing the risk of side effects caused by neurotoxin treatment.
[0017] Another object of the present invention is to provide alternative or improved means for precise control mechanisms for BoNT or TeNT expression.
[0018] Another object of the present invention is to provide alternative or improved means for the treatment or prevention of autoimmune diseases, spasms, dystonia, hyperhidrosis and / or cosmetic medicine.
[0019] These problems are addressed by the features of the independent claims. Preferred embodiments of the invention are provided by the dependent claims.
[0020] In one aspect, the present invention relates to nucleic acid molecules for regulating neuromuscular transmission, said nucleic acid molecules comprising sequences encoding one or more receptors or fragments thereof for motor endplates.
[0021] This invention stems from advances in botulinum neurotoxin (BoNT) gene therapy, as disclosed in U.S. Patent No. 11,707,510 B2. One object of this invention is to mitigate the risk of overdose associated with prolonged or overexpression of BoNT or tetanus toxin (TeNT) proteins, which may lead to systemic side effects. Although the therapeutic window for BoNT or TeNT gene therapy is significantly wider than that of currently approved BoNT or TeNT formulations, uncontrolled or overexpression poses a potential risk of overdose. For regulatory approval as a pharmaceutical product, it is necessary to minimize patient risk as much as possible by implementing precise control mechanisms for BoNT or TeNT expression.
[0022] BoNT is widely recognized for its applications in cosmetic medicine, but its crucial role in treating spasticity, dystonia, and hyperhidrosis is little known. Its mechanism of action involves inhibiting neurotransmission at the presynaptic motor endplate, leading to muscle paralysis. However, BoNT is one of the most potent known toxins, with lethal doses as low as 1 mg. The duration of its effect depends on the dose used and the BoNT serotype (usually BoNT / A). Higher doses are administered in clinical applications requiring long-term effects. However, conventional BoNT therapy delivered in solution increases systemic exposure and associated risks, including serious side effects and the possibility of BoNT immunity in patients with repeated treatments. Therefore, targeted gene delivery methods are particularly advantageous in enhancing the duration of BoNT effects while minimizing systemic toxicity.
[0023] This invention offers several significant advantages in modulating neuromuscular transmission by using nucleic acid molecules encoding one or more receptors or functional fragments thereof that encode the motor endplate. Targeted expression at the neuromuscular junction reduces systemic side effects, thereby enhancing treatment specificity and minimizing off-target effects. Furthermore, compared to conventional protein-based therapies, the nucleic acid-based approach allows for improved dose control and a wider therapeutic window because expression levels can be finely tuned at the transcriptional or translational levels. Additionally, sustained expression of the therapeutic protein at the motor endplate prolongs the duration of therapeutic effect, reducing the need for frequent dosing and improving patient compliance. In summary, these advantages position this invention as an efficient and precise strategy for modulating synaptic transmission at the neuromuscular junction.
[0024] In this embodiment, the receptor for the motor endplate is an acetylcholine receptor (AChR), preferably a nicotinic acetylcholine receptor (nAChR) or a fragment thereof.
[0025] nAChRs are particularly advantageous for use in this context due to their specialized structure, high density, and crucial function at the motor endplate. As the primary receptor in this region, nAChRs are strategically positioned within deep folds of the muscle cell membrane, designed to maximize surface area and optimize receptor availability for neuromuscular transmission. The exceptionally high density of nAChRs at the top of these folds ensures efficient signal transduction, as millions of receptors are present at each motor endplate, facilitating rapid and robust communication between motor neurons and muscle fibers. Furthermore, nAChRs play a critical role in muscle contraction by mediating the action of acetylcholine (the primary neurotransmitter at the neuromuscular junction). NAChRs initiate signaling cascades, activating muscle upon acetylcholine binding, highlighting their fundamental importance in neuromuscular function. These properties make nAChRs an ideal target for modulating synaptic transmission in therapeutic applications.
[0026] In an embodiment, the receptors of the motor endplate include at least one subunit of the acetylcholine receptor (AChR), preferably α, β, γ, δ and / or ε subunits, more preferably ε subunits.
[0027] In a preferred embodiment, the nucleic acid molecule contains at least one subunit of AChR. In a preferred embodiment, the nucleic acid molecule contains at least one ε subunit of AChR. In another embodiment, the nucleic acid molecule contains an AChR transmembrane domain of an ε subunit. In yet another embodiment, the nucleic acid molecule contains an AChR transmembrane domain of an ε subunit lacking functional AChR activity.
[0028] Nucleic acids encoding proteins with transmembrane domains of the acetylcholine receptor (AChR) possessing ε subunits but lacking functional receptor activity provide a novel and creative competitive inhibitory strategy for modulating neuromuscular transmission. By competing with endogenous functional AChRs at the motor endplate, these nonfunctional receptor variants effectively reduce the number of active AChRs, thereby reducing synaptic signaling and leading to controlled inhibition of muscle activation.
[0029] However, other receptors on the motor endplate, such as the MuSK or glutamate receptors, can also be used in this case.
[0030] In this implementation, the receptors for the motor endplate are muscle-specific receptor tyrosine kinase (MuSK) and / or glutamate receptors or fragments thereof.
[0031] In a preferred embodiment, the receptor for the motor endplate is a muscle-specific receptor tyrosine kinase (MuSK) or a fragment thereof. In this embodiment, the transmembrane domain of MuSK localizes the encoded protein to the membrane.
[0032] In this invention, MuSK offers significant advantages in regulating neuromuscular transmission via nucleic acid molecules or the present invention. MuSK is endogenously and specifically expressed in the postsynaptic membrane of the neuromuscular junction, ensuring that its coding sequence guides precise and localized expression. This specificity makes MuSK an ideal gene target for intervention to regulate synaptic function, as it plays a central role in neuromuscular synapse formation, maintenance, and signal transduction.
[0033] Incorporating a sequence encoding MuSK into a nucleic acid molecule allows for targeted modulation of motor endplate activity by enhancing or inhibiting neuromuscular transmission, depending on the needs of therapeutic or cosmetic applications. Furthermore, the transmembrane domain of MuSK can be fully utilized to ensure membrane localization of the encoded protein, thereby providing structural anchoring within the synapse. This is particularly advantageous in applications requiring precise receptor localization to influence neurotransmission dynamics. Additionally, the Ig-like extracellular domain of MuSK encoded within the nucleic acid sequence contributes to synaptic stability and can promote interactions with other synaptic components, further enhancing the efficacy of neuromodulation interventions. Therefore, in one embodiment, the nucleic acid molecule contains a sequence encoding an Ig-like extracellular domain of MuSK.
[0034] By encoding MuSK or its functional domains, nucleic acid molecules can achieve targeted expression of neuromuscular receptors while minimizing off-target effects. This gene-based approach provides a universal platform for modulating acetylcholine receptor aggregation, synaptic stability, and signal transduction at the motor endplate—key factors influencing neuromuscular function. Therefore, incorporating sequences encoding MuSK in this invention represents a highly precise, receptor-specific strategy for neuromodulation therapy, allowing for controlled modulation of synaptic activity in clinical and cosmetic applications.
[0035] In this implementation, the nucleic acid molecule is a DNA or RNA molecule.
[0036] In this implementation, the nucleic acid molecule is an mRNA molecule.
[0037] Advantageously, DNA-based approaches enable long-term and sustained expression of therapeutic proteins because DNA can stably integrate into the host genome or persist as a cell-free gene, reducing the need for repeated dosing. This prolonged expression enhances therapeutic efficacy while improving patient compliance. RNA-based approaches, particularly messenger RNA (mRNA), offer the advantage of transient expression without the risk of genomic integration, making them a safer alternative for precise, controlled therapeutic delivery. Furthermore, mRNA therapies can bypass transcriptional regulation, allowing for rapid protein synthesis and immediate therapeutic effects. Advantageously, both DNA and RNA molecules can be engineered for targeted expression, ensuring high specificity at the neuromuscular junction while minimizing systemic side effects. Moreover, advances in nucleic acid delivery systems, such as lipid nanoparticles and viral vectors, enhance the stability and cellular uptake of these molecules, further optimizing their therapeutic potential.
[0038] In this implementation, the nucleic acid molecule contains a sequence encoding a neurotoxin.
[0039] In this implementation, the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin (TeNT).
[0040] In one embodiment, the nucleic acid molecule contains a sequence encoding botulinum toxin (BoNT). In another embodiment, the nucleic acid molecule contains a sequence encoding tetanus toxin (TeNT). In yet another embodiment, the nucleic acid molecule containing a sequence encoding a neurotoxin (e.g., BoNT or TeNT) enables neuromuscular modulation. In yet another embodiment, the nucleic acid molecule containing a sequence encoding a neurotoxin (e.g., BoNT or TeNT) allows the neurotoxin to be expressed at the neuromuscular junction.
[0041] By encoding neurotoxins such as BoNT or TeNT, nucleic acid molecules advantageously enable the toxins to be targeted and locally expressed at the neuromuscular junction, thereby reducing the need for direct protein administration and minimizing systemic distribution and associated side effects. This approach allows for controlled and sustained neurotoxin production, extending therapeutic lifespan and reducing treatment frequency. Furthermore, leveraging cellular translational mechanisms ensures the efficient and regulated synthesis of neurotoxins at their intended sites of action, improving safety and efficacy. In addition, nucleic acid-based delivery avoids the stability and storage challenges of direct protein administration, providing a more robust and scalable treatment option. This strategy is particularly beneficial for conditions requiring precise neuromuscular modulation, such as spasticity disorders, dystonia, or chronic pain management.
[0042] In one embodiment, the nucleic acid molecule contains a sequence encoding a scaffold / matrix attachment region (S / MAR) element. In another embodiment, the nucleic acid molecule contains sequences encoding a neurotoxin (e.g., BoNT or TeNT) and a scaffold / matrix attachment region (S / MAR) element.
[0043] Administration of nucleic acids encoding recombinant BoNT or TeNT at the target site offers significant advantages, including higher local concentrations and prolonged therapeutic effects. By incorporating scaffold / matrix attachment region (S / MAR) elements, BoNT or TeNT expression, as well as shRNA expression, can be maintained for an extended period (potentially lasting several weeks). This prolonged expression represents a key advantage over conventional BoNT or TeNT protein administration, which requires repeated injections.
[0044] To effectively replace protein-based BoNT or TeNT therapies with nucleic acid-based approaches, the distribution of therapeutic effect must closely mimic the effects achieved through traditional BoNT or TeNT injections. Clinicians administering BoNT or TeNT injections have developed considerable expertise in selecting precise injection sites and volumes to achieve optimal therapeutic outcomes. However, nucleic acids exhibit entirely different diffusion properties compared to proteins. Unlike BoNT or TeNT proteins, which readily diffuse throughout tissues, naked nucleic acids tend to remain at the injection site, thus limiting their diffusion and overall efficacy.
[0045] This challenge can be mitigated by using transfection-enhancing vectors that not only improve cellular uptake but also promote broader distribution within target tissues (see below). Various particulate formulations, including liposomes, lipid nanoparticles (LNPs), polyethyleneimine (PEI) particles, and viral vectors, can be used to enhance nucleic acid delivery. However, these vectors can also increase the risk of off-target transfection, potentially affecting non-target tissues. For example, some LNP formulations have shown significant tropism towards organs such as the liver, spleen, and adjacent lymph nodes after intramuscular administration, raising concerns about unintended systemic effects.
[0046] In one embodiment, the nucleic acid molecule contains a sequence encoding a promoter. In another embodiment, the nucleic acid molecule contains a sequence encoding a neurotoxin such as BoNT or TeNT, a scaffold / matrix attachment region (S / MAR) element, and a promoter.
[0047] The use of tissue-specific promoters is a key strategy for further improving the specificity of nucleic acid-based BoNT or TeNT therapies and mitigating off-target expression. By restricting gene expression to the intended target cells, such promoters ensure that therapeutic effects remain localized, thereby reducing the likelihood of adverse systemic effects. This approach enhances the safety and efficacy of nucleic acid-based BoNT or TeNT therapies, making them a viable alternative to conventional BoNT or TeNT protein therapies.
[0048] In this implementation, the nucleic acid molecule contains a sequence encoding an antibody.
[0049] This approach can effectively neutralize pathological immune responses by encoding antibodies that target harmful molecules, such as autoantibodies against AChR. For example, antibodies designed to bind to the Fc region of immunoglobulins or proteins such as protein A can spatially block the binding of autoantibodies to AChR, thereby maintaining acetylcholine binding and restoring normal neuromuscular transmission. This targeting mechanism provides highly specific and localized therapeutic effects, minimizing systemic immunosuppression and associated risks. Furthermore, the continuous in vivo production of therapeutic antibodies through nucleic acid expression reduces the need for repeated antibody dosing, thereby improving patient compliance and treatment efficacy. Another advantage is the potential development of chimeric AChRs that maintain functional activity while evading autoantibody recognition, further expanding therapeutic options.
[0050] Another significant advantage is the ability to engineer highly specific antibodies suited to recognize and neutralize specific pathogenic targets, providing a level of precision difficult to achieve with conventional small molecule drugs or protein therapies. This specificity reduces off-target effects and enhances treatment safety. Furthermore, nucleic acid-based antibody production can be easily scaled up, providing a cost-effective and efficient method for generating large quantities of therapeutic antibodies without the complexities associated with traditional antibody manufacturing processes. Another advantage is the flexibility in designing antibodies with enhancing properties, such as increased affinity or reduced immunogenicity, which can improve the efficacy and safety profile of treatment. Additionally, because it is possible to encode antibodies directly within the patient's cells, this approach avoids the need for frequent intravenous administration, thereby improving patient adherence and allowing for sustained therapeutic effects over time.
[0051] In this implementation, the nucleic acid molecule contains a sequence encoding siRNA and / or shRNA.
[0052] Including sequences encoding small interfering RNA (siRNA) or short hairpin RNA (shRNA) within nucleic acid molecules offers significant therapeutic advantages, particularly in neuromuscular modulation using fusion proteins containing neurotoxins. siRNA and shRNA function by triggering RNA interference (RNAi), a natural cellular mechanism that selectively silences specific target genes at the posttranscriptional level. This gene silencing ability can enhance the efficacy and specificity of BoNT or TeNT-based therapies by downregulating genes involved in synaptic regeneration, neurotransmitter release, or immune response pathways. For example, siRNA or shRNA can be engineered to inhibit the SNARE complex protein, which promotes synaptic vesicle fusion, thus prolonging neurotoxicity and reducing the need for frequent re-dosing. Furthermore, RNAi elements can be used to target immunomodulatory genes, reducing the risk of the host developing anti-BoNT or TeNT antibodies, a major limitation of repeated neurotoxin therapy. In addition, by selectively silencing pro-apoptotic or inflammatory genes, siRNA / shRNA can help minimize off-target toxicity and adverse immune responses, ensuring more controlled and localized therapeutic effects. Therefore, integrating sequences encoding siRNA or shRNA into nucleic acid molecules represents a favorable strategy for increasing treatment duration, reducing systemic side effects, and overcoming immunogenicity-related challenges, ultimately enhancing the overall therapeutic potential of neurotoxin-based interventions.
[0053] Furthermore, incorporation of short hairpin RNA (shRNA) sequences targeting AChR expression enables gene silencing, reducing AChR levels and consequently decreasing neuromuscular signal transduction. This controlled downregulation of AChR expression facilitates precise muscle relaxation, making it a highly adaptable therapeutic strategy for conditions involving excessive or involuntary muscle contractions, such as spasticity, dystonia, or hypertonia. The combined use of various siRNA or shRNA molecules allows for fine-tuning of muscle activity, achieving customized therapeutic effects ranging from mild relaxation to complete muscle paralysis. This flexibility makes the approach suitable for both temporary and long-term neuromodulation, offering advantages over traditional pharmacological therapies by providing local, sustained, and modulated muscle inhibition while minimizing systemic side effects.
[0054] The use of siRNA offers a particularly advantageous strategy for selectively downregulating endogenous AChR expression while simultaneously enhancing transgenic expression of modified AChRs. This dual mechanism allows for targeted replacement of the native receptor at the neuromuscular endplate with a functionally optimized version. By silencing endogenous AChR through RNA interference, cellular mechanisms preferentially express and incorporate the modified receptor, ensuring its efficient integration into the synaptic membrane. This approach facilitates precise neural modulation and enables the development of custom receptor variants with improved functional properties, such as enhanced stability, reduced autoantibody binding in autoimmune diseases (e.g., myasthenia gravis), or optimized neurotransmission for therapeutic and cosmetic applications. The ability to selectively modulate the receptor composition at the motor endplate further enhances the therapeutic specificity of this strategy, minimizing off-target effects while achieving sustained and controlled neuromuscular modulation.
[0055] In one implementation, neuromuscular transmission is inhibited by downregulating receptors at the motor endplate. In another implementation, neuromuscular transmission is inhibited by downregulating AChR or Musk expression.
[0056] In another embodiment, the present invention leverages RNA interference to downregulate the expression of AChR or MuSK, thereby inhibiting neuromuscular transmission. This can be achieved by direct transfection with siRNA or by introducing a vector encoding shRNA. The use of siRNA has several advantages, including a wider range of transfection methods, such as adeno-associated virus (AAV)-mediated delivery or iontophoresis (e.g., US20110038937A1, Kigasawa et al., Int Journ Pharmac, 2010, Hasan et al., Journ Contr Rel, 2022). These techniques are well known in the art, and those skilled in the art can select appropriate methods. Furthermore, siRNA reduces the risk of immune responses against therapeutic proteins.
[0057] Furthermore, RNAi can promote the downregulation of endogenous receptor expression while simultaneously expressing modified receptors, which is particularly beneficial for treating neuromuscular disorders such as myasthenia gravis. For BoNT therapy, RNAi-mediated AChR downregulation offers a viable alternative. However, given that BoNT exerts its effects within presynaptic neurons and has a prolonged duration of action, RNAi may not be suitable for all indications, such as neuropathic pain. DNA-encoded shRNAs can be used to extend the therapeutic effect, allowing for prolonged receptor downregulation.
[0058] In this implementation, the nucleic acid molecule contains a sequence that encodes a linker.
[0059] In one embodiment, the nucleic acid molecule comprises a sequence encoding one or more adapters. In another embodiment, the nucleic acid molecule comprises a sequence encoding an adapter according to SEQ ID NO. 9. In yet another embodiment, the nucleic acid molecule comprises sequences encoding 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 adapters, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 adapters.
[0060] Additional DNA plasmids were constructed to enhance the effectiveness of BoNT or TeNT-mediated interactions by incorporating modifications to adapter sequences.
[0061] In one implementation of the plasmid construct, a single GGGGS connector is replaced by an eight-fold connector, thereby increasing the flexibility and spatial separation of the connected structural domains.
[0062] In another implementation, the GGGGS linker is replaced by a five-fold repeat sequence in the hinge region of human immunoglobulin G (IgG), which is known to provide structural stability and flexibility.
[0063] In another embodiment, the quadruple connector is followed by a thrombin cleavage site, enabling proteolytic hydrolysis under specific conditions.
[0064] Surprisingly, these modifications were found to lead to a significant improvement in BoNT-induced paralysis, suggesting that linker extension and structural optimization contribute to enhancing the functional activity of the expressed fusion protein.
[0065] This invention also provides highly localized and targeted modification of synaptic function, ensuring that therapeutic effects are strictly confined to the treated muscle. This targeted approach significantly reduces the risk of systemic side effects because the modified protein is primarily expressed within the synaptic cleft, preventing accidental diffusion into surrounding tissues. Furthermore, due to the restricted expression of recombinant proteins at the motor endplate, this invention provides a precise and self-regulating drug delivery mechanism. Because the amount of recombinant protein integrated into the muscle membrane is inherently limited, any excess protein not incorporated into the membrane is rapidly degraded by the proteasome system within the cytosol. This is particularly advantageous for the expression of potent therapeutic proteins such as BoNT or TeNT, where conventional drug delivery of recombinant proteins is difficult to control. This invention significantly increases the therapeutic window by restricting expression to the neuromuscular junction, thus providing a significantly higher safety margin than direct protein delivery. Regarding BoNT or TeNT fusion proteins, as described below, this approach enables a minimum five-fold increase in therapeutic reach, exceeding any previously established delivery system. This controlled and localized expression strategy represents a breakthrough in neuromuscular modulation, providing unprecedented precision, efficacy, and safety in therapeutic applications.
[0066] In one aspect, the present invention relates to nucleic acid vectors comprising nucleic acid molecules according to the invention, wherein the vector is a viral vector, such as a lentiviral vector or a retroviral vector, a transposon, an RNA vector, or nanoparticles, such as lipid nanoparticles, liposomes, or polyethyleneimine (PEI).
[0067] In an embodiment, the nucleic acid molecule comprises a sequence according to SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8 or SEQ ID NO.9, or a sequence having at least 70%, 80%, 90% or 95% sequence identity with it.
[0068] In embodiments, the disclosed construct may encode a fusion protein comprising at least a transmembrane domain of the ε-subunit (M2) of an acetylcholine receptor (AChR) or a transmembrane domain of a muscle-specific kinase (MuSK). In one embodiment, the transmembrane domain is operatively linked to a functional protein capable of modulating presynaptic neuronal activity. Such functional proteins may include, but are not limited to, BoNT or TeNT, which exert neurotoxic effects on presynaptic neurons, or antibodies that specifically bind to synaptic active structures, such as acetylcholine. Through this binding, the antibody can inhibit the biological activity of the target molecule or promote its accumulation at the synapse, thereby modulating neurotransmission.
[0069] In one aspect, the present invention relates to fusion proteins, preferably comprising one or more features of the present invention, said fusion protein comprising:
[0070] a) Receptors and / or fragments thereof of the motor endplate, wherein the receptors of the motor endplate are acetylcholine receptors (AChR), muscle-specific receptor tyrosine kinases (MuSK), and / or glutamate receptors and / or fragments thereof, and / or
[0071] b) Neurotoxins, wherein the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin.
[0072] In one aspect, the present invention relates to fusion proteins, preferably comprising one or more features of the present invention, said fusion protein comprising:
[0073] a) Receptors and / or fragments thereof of the motor endplate, wherein the receptors of the motor endplate are acetylcholine receptors (AChR), muscle-specific receptor tyrosine kinases (MuSK), and / or glutamate receptors and / or fragments thereof, and / or
[0074] b) Neurotoxins, wherein the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin, and / or
[0075] c) Connector.
[0076] In one aspect, the present invention relates to fusion proteins, preferably comprising one or more features of the present invention, said fusion protein comprising:
[0077] a) Receptors and / or fragments thereof of the motor endplate, wherein the receptors of the motor endplate are acetylcholine receptors (AChR), muscle-specific receptor tyrosine kinases (MuSK), and / or glutamate receptors and / or fragments thereof, and / or
[0078] b) Neurotoxins, wherein the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin, and / or
[0079] c) Connectors, and / or
[0080] d) siRNA or shRNA.
[0081] In one aspect, the present invention relates to fusion proteins, preferably comprising one or more features of the present invention, said fusion protein comprising:
[0082] a) Receptors and / or fragments thereof of the motor endplate, wherein the receptors of the motor endplate are acetylcholine receptors (AChR), muscle-specific receptor tyrosine kinases (MuSK), and / or glutamate receptors and / or fragments thereof, and / or
[0083] b) Neurotoxins, wherein the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin, and / or
[0084] c) Connectors, and / or
[0085] d) siRNA or shRNA, and / or
[0086] e) Scaffold / matrix attachment area (S / MAR) elements and / or
[0087] f) Promoter.
[0088] In an embodiment, the fusion protein comprises a sequence according to SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8 or SEQ ID NO.9, or a sequence having at least 70%, 80%, 90% or 95% sequence identity with it.
[0089] To mitigate the risks of BoNT or TeNT release, BoNT or TeNT proteins can be anchored to the cell membrane via adaptor sequences that attach to transmembrane domains. However, the ubiquitous expression of BoNT or TeNT across the entire cell membrane presents two major drawbacks. First, BoNT or TeNT molecules displayed on the membrane surface can trigger immunogenic responses, potentially impairing therapeutic efficacy or inducing adverse immune reactions. Second, there is a risk of accidental extracellular release of BoNT or TeNT, which can lead to off-target effects and reduced localization specificity. Therefore, strategies have been devised to specifically restrict BoNT or TeNT expression to the motor endplate to circumvent these limitations, thereby ensuring targeting function while minimizing immunogenicity and accidental spread.
[0090] Therefore, specifically restricting BoNT or TeNT expression to the motor endplate offers several significant advantages. Localizing BoNT to this precise anatomical site enhances targeted delivery and therapeutic efficacy while minimizing systemic exposure. This spatially controlled expression reduces the risk of immunogenic responses that could arise from widespread membrane presentation, thereby improving biocompatibility and reducing potential immune clearance. Furthermore, restricting BoNT or TeNT to the motor endplate advantageously mitigates the risk of accidental extracellular release, ensuring that the neurotoxin remains confined to its intended site of action. This localization also enhances safety by preventing off-target effects that could disrupt neuromuscular function in unexpected areas. Overall, these advantages optimize the therapeutic efficacy of BoNT or TeNT while addressing key challenges associated with their expression and delivery.
[0091] In a further embodiment, proteins that function within the synaptic cleft are fused, such as acetylcholinesterase, which catalyzes the hydrolysis of acetylcholine. This fusion results in a localized decrease in the concentration of acetylcholine at the receptor site, thereby reducing or inhibiting neuromuscular transmission. Alternatively, the reduction in excitatory signal transmission and subsequent reduction in muscle tone can be achieved by expressing modified AChRs. These modified AChRs maintain a closed, non-functional conformation and compete with endogenous wild-type receptors for binding to the neuromuscular junction. By replacing the functional wild-type receptor, the sensitivity of muscle cells to acetylcholine-mediated stimuli is effectively reduced, thereby modulating neuromuscular activity.
[0092] Preferred sequence
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119]
[0120]
[0121] In one aspect, the present invention relates to an in vitro method for modulating neuromuscular transmission, said in vitro method comprising transfecting eukaryotic cells with a nucleic acid molecule according to the invention.
[0122] The in vitro method for modulating neuromuscular transmission disclosed in this invention offers several significant advantages for research, therapeutic development, and clinical application. By transfecting eukaryotic cells with the nucleic acid molecules of this invention, the method can control the expression of therapeutic proteins, antibodies, neurotoxins, or RNA interference molecules, thereby facilitating precise studies of their effects on neuromuscular function. This in vitro method provides a reliable and reproducible platform for studying synaptic modulation under defined conditions, allowing for the identification and optimization of effective therapeutic constructs prior to in vivo application. Furthermore, it enables high-throughput screening of a wide range of nucleic acid sequences to assess their efficacy, stability, and safety, thereby accelerating the development of novel neuromodulation therapeutics. Additionally, by using patient-derived cells, this technology offers potential applications in personalized medicine, allowing for the development of individualized treatment strategies based on a patient's specific genetic and molecular characteristics.
[0123] In this embodiment, the eukaryotic cells are skeletal muscle cells, smooth muscle cells, and / or skin cells.
[0124] Skeletal muscle cells exhibit high transfection efficiency, and intramuscular or intradermal administration of naked plasmid DNA or RNA via a suitable transfection vector enables local recombinant protein expression in the target tissue. This approach has been extensively studied and validated in previous studies (e.g., Davis et al., Hum Gene Ther, 1993; Danko et al., Vaccine, 1994). By employing a gene-based strategy for local BoNT or TeNT expression, this invention addresses a key limitation of current treatment methods, providing more controlled and sustained modulation of neuromuscular transmission.
[0125] Skin cells (including fibroblasts and keratinocytes) serve as an accessible and robust platform for ex vivo gene therapy applications, where patient-derived cells can be modified to express therapeutic agents and subsequently reintroduced into the body. The use of nucleic acid molecules in skin cells enables sustained systemic or local release of therapeutic proteins, antibodies, or RNA interference molecules, providing a non-invasive alternative for neuromuscular modulation. This approach is particularly advantageous for patients requiring long-term treatment, as genetically modified skin cells can serve as a continuous source of therapeutic agents without the need for repeated drug administration. Furthermore, this strategy allows for personalized and patient-specific therapies, optimizing therapeutic efficacy while minimizing immune rejection or off-target effects, because skin cells can be readily harvested, modified, and expanded ex vivo prior to transplantation. The use of transfected skin cells also holds potential for cosmetic applications, such as reducing excessive muscle activity in cosmetic drugs by providing localized and controlled neuromodulation without the need for repeated toxin injections.
[0126] In a preferred embodiment, the present invention relates to an in vitro method for modulating neuromuscular transmission, the in vitro method comprising transfecting skeletal muscle cells, smooth muscle cells and / or skin cells with a nucleic acid molecule according to the invention to modulate the transmembrane domain of an acetylcholine receptor (AChR) with the ε subunit and / or transmembrane domain of a muscle-specific receptor tyrosine kinase (MuSK).
[0127] In one aspect, the present invention relates to cells comprising genetically modified nucleic acid molecules, vectors, and / or fusion proteins according to the present invention.
[0128] In this embodiment, the cell is a eukaryotic cell selected from the group consisting of skeletal muscle cells, smooth muscle cells, or skin cells.
[0129] In embodiments, the genetically modified cells according to the present invention are used to treat or prevent autoimmune diseases, spasms, dystonia, hyperhidrosis, myasthenia gravis, and / or cosmetic medicine.
[0130] In one embodiment, the genetically modified cells according to the present invention are used for cosmetic treatments.
[0131] Another advantage of using nucleic acid-based methods for recombinant protein expression lies in the precise dosing control of expression specific to the motor endplate. This targeted expression inherently limits the amount of recombinant protein integrated into the muscle membrane, as proteins exceeding membrane capacity are rapidly degraded in the cytosol via the proteasome pathway. This mechanism is particularly advantageous for highly potent and potentially toxic proteins such as BoNT or TeNT, where precise dosing control is crucial to ensuring efficacy and safety.
[0132] In conventional protein administration, the total amount of BoNT or TeNT delivered to the system can be accurately measured, but protein diffusion and localization remain difficult to control. Conversely, when administering nucleic acids encoding BoNT or TeNT, the exact amount of translated protein cannot be predetermined with the same precision. However, by fully utilizing the natural limitations of expression at the motor endplate, the risk of excessive protein accumulation and systemic toxicity is significantly reduced. This results in a substantial widening of the therapeutic window compared to protein-based BoNT or TeNT therapies.
[0133] Targeted expression strategies enable significantly higher local doses at precise sites of action while maintaining systemic safety. Surprisingly, in the case of BoNT fusion proteins, this approach has shown an at least five-fold increase in therapeutic reach, a level of control and safety not yet achieved with any other BoNT delivery system. Therefore, this innovation represents a major advance in neuromuscular modulation therapy, providing enhanced efficacy while minimizing the risk of side effects.
[0134] Multiple aspects of this invention are unified, benefited from, based on, and / or associated with the structural and / or functional characteristics (including functional properties and beneficial technical effects) of the nucleic acid molecules used to modulate neuromuscular transmission as described herein. Features disclosed in the context of nucleic acid molecules are also applicable to and considered to be disclosed in the context of nucleic acid vectors, fusion proteins, in vitro methods, genetically modified cells, and vice versa. Any feature disclosed in any other aspect of this invention, such as nucleic acid vectors, fusion proteins, in vitro methods, genetically modified cells, or their medical use, is also considered to be disclosed in the context of nucleic acid molecules of this invention, and vice versa. Detailed Implementation
[0135] This invention relates to nucleic acid molecules for regulating neuromuscular transmission, the nucleic acid molecules containing sequences encoding one or more receptors or fragments thereof for motor endplates.
[0136] The motor endplate, also known as the neuromuscular junction (NMJ), is a specialized chemical synapse between the terminal end of a motor neuron and a muscle fiber. It facilitates the transmission of action potentials from the nerve to the muscle, thereby triggering muscle contraction. Structurally, the NMJ comprises three key components: the presynaptic nerve ending, the synaptic cleft, and the postsynaptic motor endplate. The presynaptic nerve ending contains synaptic vesicles filled with acetylcholine (ACh), which is synthesized from choline and acetyl-CoA via choline acetyltransferase. Upon depolarization, voltage-gated calcium channels open, allowing calcium inflow and triggering fusion of the synaptic vesicles with the presynaptic membrane. ACh is then released into the synaptic cleft via exocytosis mediated by the SNARE protein. The 50-nanometer-wide synaptic cleft contains acetylcholinesterase (AChE), which rapidly hydrolyzes ACh to terminate its function. The postsynaptic motor endplate (a highly folded region of the muscle fiber's sarcolemma) is densely packed with receptors at a density of approximately 10,000 receptors / μm. 2 The nicotinic acetylcholine receptor (nAChR) is a ligand-gated ion channel composed of α, β, ε, and δ subunits. Binding to ACh leads to sodium ion influx, membrane depolarization, and the generation of an endplate potential (EPP). If sufficient, the EPP triggers an action potential that propagates along the muscle fiber, ultimately causing muscle contraction via excitation-contraction coupling. Dysfunction at the NMJ, whether due to genetic mutations, autoimmune diseases (e.g., myasthenia gravis, Lambert-Eton syndrome), or neurotoxins (e.g., botulinum toxin), can disrupt synaptic transmission, leading to neuromuscular diseases characterized by muscle weakness or hyperexcitability.
[0137] In the context of this invention, the motor endplate serves as a key anatomical and functional site for the targeted modulation of neuromuscular transmission. As the postsynaptic membrane of the neuromuscular junction, the motor endplate contains key receptors, including AChR and MuSK, which mediate synaptic transmission from motor neurons to muscle fibers, thereby modulating muscle contraction. This invention leverages the specificity of receptor expression at the motor endplate to achieve localized and controlled therapeutic effects by applying nucleic acids, fusion proteins, or RNAi elements encoding modified receptors. By restricting the expression of therapeutic agents (e.g., BoNT, TeNT, or acetylcholinesterase) at the motor endplate, this invention mitigates systemic exposure and reduces off-target effects, thereby enhancing efficacy and safety. Furthermore, this invention can downregulate or modify AChR to reduce muscle excitability through RNA interference mechanisms (including shRNA or siRNA) or by expressing dysfunctional receptor variants that competitively inhibit wild-type receptor function. Additionally, by using genomic elements such as scaffold / matrix attachment regions (S / MARs) and tissue-specific promoters, this invention ensures sustained but controlled therapeutic effects, preventing excessive protein expression and associated toxicity. This targeted approach expands the therapeutic window of BoNT or TeNT-based therapeutics and provides a novel gene therapy strategy. Therefore, the motor endplate, as the primary site of action in this invention, can precisely, locally, and persistently modulate neuromuscular function through genetic intervention.
[0138] As used herein, the term "receptor of the motor endplate" refers to any receptor present at the motor endplate. Non-limiting examples are acetylcholine receptors, such as nicotinic acetylcholine receptors (nAChR) or muscarinic acetylcholine receptors (mAChR), and non-acetylcholine receptors, such as glutamate receptors, ATP receptors, and neuropeptides.
[0139] Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that respond to acetylcholine and certain exogenous agonists such as nicotinic acid. As members of the cysteine ring superfamily, nAChRs are pentamer transmembrane proteins composed of various subunits that define their function and pharmacological properties. These receptors promote synaptic transmission by regulating the flux of Na+, K+, and in some cases Ca2+ ions upon agonist binding, leading to cellular depolarization. There are two main types of nAChRs: the muscular type, expressed at the neuromuscular junction (Nm), and the neural type (Nn), distributed throughout the central and peripheral nervous systems. The muscular nAChR mediates excitatory neurotransmission at the neuromuscular synapse, while the neural receptor contributes to autonomic ganglion signaling, catecholamine release, and cognitive processes. The functional diversity of nAChRs stems from their subunit composition, in which vertebrate receptors bind α (α1–α10) and β (β1–β4) subunits, forming homologous or heterologous assemblies. The binding of acetylcholine to its two α-subunit sites induces conformational changes, leading to channel opening and ion conduction. nAChR is involved in a variety of physiological functions, such as regulation of neurotransmitter release, synaptic plasticity, and inflammatory responses. Pharmacologically, nAChR is targeted by agonists (e.g., nicotine, epibatidine), competitive antagonists (e.g., hexamethyldiammonium, α-cladosporin), and allosteric modulators. Dysregulation of nAChR activity is associated with conditions including myasthenia gravis, congenital myasthenia gravis syndrome, nicotine addiction, and neurodegenerative diseases.
[0140] Acetylcholine receptor (nAChR) subunits are protein components that assemble into pentamer structures to form functional nicotinic acetylcholine receptors, which mediate synaptic transmission in response to acetylcholine and other ligands. Seventeen nAChR subunits have been identified in mammals, classified into muscular (α1, β1, δ, γ, and ε) and neuronal (α2-α10, β2-β4) subunits. These subunits combine in specific stoichiometric combinations to produce receptor subtypes with different pharmacological and functional properties. The muscular receptor exists as a heteropentamer, transforming from the embryonic form (α1)2β1δγ to the adult form (α1)2β1δε, in which the ε subunit replaces the γ subunit shortly after birth. The ε subunit, encoded by the CHRNE gene, plays a crucial role in stabilizing the receptor complex, enhancing synaptic efficiency, and regulating receptor clustering at the neuromuscular junction. Mutations in CHRNE are a major cause of congenital myasthenia gravis (CMS), leading to a lack of endplate acetylcholine receptors and altered receptor dynamics. These mutations (usually autosomal recessive) impair receptor function by disrupting ligand binding, gating efficiency, and channel opening probability, which can lead to severe neuromuscular injury. The presence of ε subunit-specific mutations introduces arginine residues into the ligand-binding pocket, illustrating the far-reaching functional consequences of structural alterations, significantly reducing agonist affinity and gating efficiency. The regulated expression and assembly of nAChR subunits (including the ε subunit) are tightly controlled to maintain receptor fidelity and optimal neuromuscular transmission, thereby ensuring proper synaptic signaling and muscle function.
[0141] Muscle-specific kinases (MuSKs) are receptor tyrosine kinases crucial for the development, organization, and maintenance of the neuromuscular junction (NMJ), in which motor neurons connect to skeletal muscle fibers. MuSK activation occurs through its interaction with low-density lipoprotein receptor-associated protein 4 (LRP4), a transmembrane protein, and is enhanced by the release of the heparan sulfate proteoglycan agrin from motor neurons. The activation cascade involves the autophosphorylation of MuSK and the recruitment of key intracellular signaling molecules, including casein kinase 2 (CK2), downstream kinase 7 (Dok-7), and rapsyn, leading to the aggregation of acetylcholine receptors (AChRs) at the postsynaptic membrane. This process ensures efficient synaptic transmission and muscle contraction. Disruption of MuSK function, whether due to genetic mutations or autoantibodies, can lead to neuromuscular diseases such as congenital myasthenia gravis and myasthenia gravis. MuSK-associated myasthenia gravis is characterized by autoantibodies that impair agrin / LRP4-mediated signaling, resulting in defective NMJ formation and transmission. MuSK mutations, including frameshift and missense mutations, further impair NMJ integrity by disrupting receptor expression, signal transduction, or AchR aggregation.
[0142] As used herein, AChR and MuSK serve as fundamental molecular targets for regulating neuromuscular transmission. This invention leverages the highly specific expression of these receptors to achieve local gene therapy for neuromuscular diseases. This invention enables precise modulation of neuromuscular excitability by utilizing nucleic acids encoding modified AChR or MuSK, RNAi strategies, or fusion proteins. AChR can be downregulated via siRNA or shRNA to reduce acetylcholine-mediated signaling, thereby decreasing muscle tone in conditions such as spasticity, dystonia, and hyperhidrosis. Furthermore, this invention allows for the expression of modified AChR variants that maintain a closed conformation, competitively inhibiting functional wild-type receptors and further reducing muscle responsiveness to neural stimulation. Similarly, MuSK expression can be modulated to affect AChR aggregation and synaptic integrity, providing additional mechanisms for finely modulating neuromuscular transmission. Moreover, this invention enables targeted delivery of therapeutic proteins (such as BoNT or TeNT) by fusing them into the transmembrane domains of AChR or MuSK, ensuring local expression at the motor endplate while minimizing systemic exposure and associated risks. Therefore, AChR and Musk are core elements of the strategy of this invention to achieve controllable and durable therapeutic effects on neuromuscular diseases through these mechanisms.
[0143] Neurotoxins are a broad class of exogenous and endogenous compounds that disrupt the structure or function of neural tissue, leading to neurotoxicity. They interfere with neuronal communication, ion channel function, or neurotransmitter release, typically resulting in excitotoxicity, apoptosis, or systemic nervous system dysfunction. Among neurotoxins, botulinum toxin (BoNT) and tetanus toxin (TeNT), produced by Clostridium bacteria, are significant due to their potent effects on synaptic transmission. BoNT inhibits acetylcholine release at the neuromuscular junction by cleaving the SNARE protein, essential for vesicle fusion, thereby causing flaccid paralysis. Despite being the most potent known biotoxin, it has therapeutic applications in neuromuscular disorders, cosmetics, and pain management. Structurally similar to BoNT, TeNT also cleaves the SNARE protein but targets inhibitory interneurons in the central nervous system, leading to uncontrolled muscle contractions and spastic paralysis. Unlike BoNT, TeNT undergoes retrograde transport to the spinal cord, disrupting inhibitory neurotransmission and causing the tetanic contractions characteristic of tetanus. Both toxins illustrate the specificity and efficacy of neurotoxins in regulating nerve function.
[0144] The terms and abbreviations “botulinum toxin neurotoxin (BoNT or BTX)” or “botulinum toxin” are used interchangeably and refer to a class of highly potent neurotoxic proteins produced by Clostridium botulinum and related bacterial species. These toxins act as inhibitors of acetylcholine release and neuromuscular blockers, preventing nerve transmission at the neuromuscular junction, thereby inducing flaccid paralysis. BoNT is classified into seven major serotypes (AG), with types A and B being the most clinically relevant because they can induce botulism in humans and are widely used in medical and cosmetic applications. The mechanism of action involves receptor-mediated endocytosis, translocation of light chains into the cytoplasm, and proteolytic cleavage of SNARE proteins (particularly SNAP-25, synaptic vesicle proteins, or synaptic binding proteins), leading to inhibition of synaptic vesicle fusion and neurotransmitter release. BoNT is used therapeutically for conditions such as muscle spasms, dystonia, strabismus, chronic migraines, hyperhidrosis, and various neurological disorders. Cosmetic applications include temporarily reducing dynamic facial wrinkles by targeting muscle paralysis. Commercial formulations include onabotulinum toxin A (Botox), abobotulinum toxin A (Dysport), incobotulinum toxin A (Xeomin), botulinum toxin type A (daxibotulinum toxin A) (Daxify), letibotulinum toxin A (Letybo), and botulinum toxin type B (rimabotulinum toxin B) (Myobloc). Adverse effects may be caused by accidental toxin spread, leading to local or generalized muscle weakness, ptosis, dysphagia, or, in severe cases, respiratory damage.
[0145] BoNTs interact with the presynaptic membrane of neurons at the neuromuscular junction to inhibit neurotransmitter release, leading to flaccid paralysis. This process begins with BoNTs binding to specific surface receptors on the presynaptic membrane, including gangliosides (GT1b, GD1b) and protein receptors such as synaptokines or SV2, facilitating their uptake via receptor-mediated endocytosis. Once inside the neuron, acidification of the vesicles triggers a conformational change in the toxin, allowing the heavy chain to translocate the light chain into the cytoplasm. The light chain is a zinc-dependent protease that then selectively cleaves essential SNARE proteins, such as SNAP-25, VAMP, or synaptic fusion proteins, depending on the BoNT serotype, disrupting the synaptic vesicle fusion process required for acetylcholine release. Consequently, the neuron cannot transmit signals to the muscle, resulting in paralysis. The effects of BoNTs persist until the neuron regenerates functional SNARE proteins and restores synaptic activity.
[0146] Tetanus toxin (TeNT) is a potent neurotoxin produced by Clostridium tetani that causes tetanus by interfering with the release of neurotransmitters in the central nervous system. The toxin contains a 150 kDa protein cleaved into a 100 kDa heavy chain (B chain) and a 50 kDa light chain (A chain) subunit. The B chain binds to specific gangliosides and GPI-anchored proteins on the presynaptic membrane of neurons, promoting their internalization. Once internal, TeNT is retrogradely transported to the spinal cord via axons, where it is transcribed into inhibitory interneurons. The A chain is a zinc-dependent protease that cleaves synaptic vesicle proteins (VAMPs) (key proteins involved in vesicle fusion), thereby preventing the release of inhibitory neurotransmitters such as GABA and glycine. This blockade leads to inhibition of motor neurons, resulting in muscle stiffness and spasms. The main clinical manifestations of tetanus include muscle spasms, sciatica, trismus, and opisthotonus. TeNT specifically acts on synaptic vesicles, leading to selective blockade of neurotransmitter release in inhibitory neurons, resulting in tetanus-associated pathological muscle activity.
[0147] In the context of this invention, BoNT and TeNT are used as key therapeutic agents to modulate neuromuscular transmission by selectively inhibiting synaptic vesicle exocytosis at the neuromuscular junction. BoNT works by cleaving SNARE proteins, thereby preventing the release of acetylcholine from presynaptic nerve endings and inducing temporary paralysis of the target muscle. This mechanism is widely used to treat excessive neuromuscular activity, such as spasticity, dystonia, and hyperhidrosis. However, systemic exposure to BoNT carries the risk of serious side effects, thus requiring precise localization of its activity. This invention addresses this challenge by encoding BoNT in a nucleic acid construct capable of specifically targeting expression at the motor endplate using a motor endplate-specific promoter, a transmembrane domain of AChR or Musk, and a fusion protein. This targeting approach increases the therapeutic scope while reducing systemic toxicity. Additionally, TeNT, which acts in the opposite manner to BoNT by preferentially targeting inhibitory interneurons in the central nervous system, results in unregulated excitatory neurotransmission and sustained muscle contraction. In this invention, TeNT can be used in controlled applications to modulate neuronal signaling within a therapeutic context of enhanced synaptic activity. By fully utilizing the high specific activity of BoNT and TeNT and improving their delivery through a nucleic acid-based expression system, this invention achieves precise neuromodulation, significantly improving the safety and efficacy of toxin-based therapies for neuromuscular diseases.
[0148] As used herein, "fusion protein" refers to a genetically engineered chimeric protein composed of two or more distinct functional domains covalently linked to produce a single polypeptide with combinatorial or enhancing properties. As used herein, fusion proteins are engineered to improve the pharmacokinetics, specificity, or functionality of therapeutic agents.
[0149] Regarding botulinum neurotoxin (BoNT) or tetanus toxin (TeNT), fusion proteins are engineered to optimize their therapeutic potential by enhancing target specificity, increasing duration of action, or modulating cellular uptake and intracellular activity. In one embodiment, this is achieved by fusing BoNT or TeNT with a targeting ligand, receptor-binding domain, or translocation-enhancing sequence, promoting selective delivery to the neuromuscular junction while reducing off-target effects. Additionally, in one embodiment, the fusion protein can modify the intracellular processing of the neurotoxin, ensuring controlled cleavage of SNARE proteins and finely modulating the degree of neuromuscular inhibition.
[0150] In the context of this invention, fusion proteins serve as key components for targeted and controlled modulation of neuromuscular transmission. Fusion proteins are engineered to combine functional domains of BoNT or other therapeutic agents with transmembrane domains derived from AChR or MuSK, thereby ensuring precise localization at the motor endplate. By incorporating connective sequences, such as glycine-serine repeats or immunoglobulin-like hinge regions, this invention optimizes the spatial conformation and stability of these fusion constructs, enhancing their therapeutic efficacy. Compared to conventional protein-based therapies, the targeted expression of these fusion proteins at the neuromuscular junction minimizes systemic toxicity and allows for significantly prolonged duration of action. Furthermore, fusion proteins can be engineered to include protease-sensitive cleavage sites, enabling controlled activation or inactivation within the synaptic cleft. This approach provides a higher degree of specificity and reduces the risk of accidental neurotoxin spread, thereby increasing the therapeutic range. Through the integration of fusion proteins into nucleic acid constructs, this invention establishes a novel and precise approach to neuromodulation, making it particularly advantageous for treating conditions such as spasticity, dystonia, and other disorders associated with abnormal neuromuscular signaling.
[0151] In a preferred embodiment, the fusion protein comprises receptors for the motor endplate, neurotoxins, antibodies, and / or RNA interference elements, allowing for precise and sustained modulation of neuromuscular transmission. The receptor component may include AChR, Musk, and / or glutamate receptors, thereby ensuring targeted localization at the motor endplate. The neurotoxin component may include BoNT and / or TeNT, enabling selective inhibition of neurotransmitter release and modulation of synaptic activity. Furthermore, the fusion protein may incorporate siRNA or shRNA, which silences specific genes involved in neuromuscular signaling or immune responses, potentially reducing immunogenicity, prolonging therapeutic effects, or enhancing selectivity. By combining these elements, such fusion proteins provide a novel approach for improving BoNT-based therapies, ensuring long-term and local effects, minimizing systemic toxicity, reducing treatment frequency, and mitigating immune responses that may impair long-term efficacy.
[0152] As used herein, the term "polynucleotide" or "nucleic acid molecule" refers to any nucleic acid molecule, such as DNA or RNA, such as messenger RNA (mRNA), RNA, genomic RNA (gRNA), positive-strand RNA (RNA(+)), negative-strand RNA (RNA(-)), genomic DNA (gDNA), complementary DNA (cDNA), or recombinant DNA. Polynucleotides include single-stranded and double-stranded polynucleotides. Preferably, the polynucleotides of the present invention comprise polynucleotides or variants having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any reference sequence described herein, typically wherein the variant retains at least one biological activity of the reference sequence. In various illustrative embodiments, the present invention is partly contemplated regarding polynucleotides comprising expression vectors, viral vectors, transfer plasmids, and compositions, as well as cells comprising them.
[0153] Polynucleotides can be prepared, manipulated, and / or expressed using a variety of well-established techniques known and available in the art. To express a desired polypeptide, the nucleotide sequence encoding that polypeptide can be inserted into a suitable vector. Examples of vectors are plasmids, autonomously replicating sequences, and transposable elements. Other exemplary vectors include, but are not limited to, plasmids, phagemids, granules, artificial chromosomes (such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC)), bacteriophages (such as λ phage or Ml 3 phage), and animal viruses. Examples of animal virus classes that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and multivacuolar papillomaviruses (e.g., SV40). Examples of expression vectors are the pClneo vector (Promega) for expression in mammalian cells; and pLenti4 / V5-DEST for lentivirus-mediated gene transfer and expression in mammalian cells. TM pLenti6 / V5-DEST TM and pLenti6.2 / V5-GW / lacZ (Invitrogen).
[0154] As used herein, the term "retrovirus" refers to an RNA virus that reverse-transcribes its genomic RNA into a linear double-stranded DNA copy and subsequently covalently integrates its genomic DNA into the host genome. Once integrated into the host genome, the virus is referred to as a "provirus." The provirus serves as a template for RNA polymerase II and directs the expression of RNA molecules that encode the structural proteins and enzymes required to produce new viral particles. Exemplary retroviruses suitable for a particular implementation include, but are not limited to: Moloney mouse leukemia virus (M-MuLV), Moloney mouse sarcoma virus (MoMSV), Harvey mouse sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibberish leukemia virus (GaLV), feline leukemia virus (FLV), foam virus, Fried mouse leukemia virus, mouse stem cell virus (MSCV), and Raul's sarcoma virus (RSV), and lentiviruses.
[0155] As used herein, the term "lentivirus" refers to a group (or genus) of complex retroviruses. Exemplary lentiviruses include, but are not limited to, HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2); Medi-Wesner virus (VMV); caprine arthritis encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV).
[0156] The term "vector" is used herein to refer to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule. The transferred nucleic acid is typically linked to, for example, inserted into, the vector nucleic acid molecule. Vectors may include sequences that guide autonomous replication within the cell, or sequences sufficient to allow integration into the host cell's DNA. Commonly used vectors include, for example, plasmids (e.g., DNA plasmids or RNA plasmids), transposons, granules, bacterial artificial chromosomes, and viral vectors. Commonly used viral vectors include, for example, replication-defective retroviruses and lentiviruses.
[0157] As will be apparent to those skilled in the art, the term "viral vector" is widely used to refer to nucleic acid molecules (e.g., transfer plasmids) that contain viral-derived nucleic acid elements that typically facilitate the transfer or integration of nucleic acid molecules into the cellular genome, or viral particles that mediate nucleic acid transfer. Viral particles typically contain a variety of viral components and sometimes include host cell components in addition to nucleic acids.
[0158] The term "viral vector" can refer to a virus or viral particle capable of transferring nucleic acid into a cell, or the transferred nucleic acid itself. Viral vectors and transfer plasmids contain structural and / or functional genetic elements primarily derived from viruses. The term "retroviral vector" refers to a viral vector or plasmid containing structural and functional genetic elements, or portions thereof, primarily derived from retroviruses.
[0159] In a preferred embodiment, the present invention relates to a method for transfecting cells with nucleic acid molecules according to the present invention.
[0160] Transposable elements are natural, nonviral gene delivery vectors that mediate stable genome integration. Sleeping Beauty (SB) transposons can cut and paste target nucleic acid sequences into the genome, providing a basis for long-term, permanent transgenic expression in transgenic cells and organisms, in which case immune cells, preferably T cells, are transformed with the nucleic acid sequence encoding CAAR of this invention. The SB transposon system is relatively well-characterized and has been extensively engineered for efficient gene delivery and discovery in various vertebrates, including humans. Those skilled in the art can identify suitable variants of the SB system and incorporate them into this invention as needed. Specific, non-limiting examples are provided below. The SB system is a safe and easy-to-use vector that enables the cost-effective and rapid preparation of therapeutic doses of cell products.
[0161] Typically, a transposon system consists of a transposon and a transposase. The transposon acts as a vector, carrying the gene to be inserted into the genome. The transposase is the so-called "main force" of the system, catalyzing the transposition process. The transposase is located between the inverted terminal repeat (ITR) sequences of the transposon. Importantly, the transposase gene can be replaced with any target nucleic acid sequence, and when the transposase is encoded by a separate trans plasmid, the transposase can control the transposition event. The physical separation of the transposon and transposase allows for optimization of the transposon-to-transposase ratio and also provides the transposase with freedom in the form of mRNA rather than DNA. First, the transposase recognizes the transposon and binds to the ITR. During synaptic complex formation, the transposase monomer brings the transposon ends together (presumably forming a tetramer). The transposase creates a double-strand break in DNA upon excision and a single-strand gap at the integration site. The pre-integration complex containing the transposon-bound transposase integrates into the host genome. SB transposition is a highly coordinated response that effectively filters out aberrant and toxic transposition intermediates (see Narayanavari & Izsvák, Cell & Gene Therapyinsights, 2017).
[0162] Previous optimization of nucleotide residues (including mutations, deletions, and additions) within the ITR of the original SB transposon (pT) has resulted in improved transposon versions, such as pT2, pT3, pT2B, and pT4, which can be used for the fusion protein coding sequences described herein.
[0163] Another aspect of the invention relates to immune cells comprising nucleic acid molecules or vectors as described herein and / or genetically modified cells expressing fusion proteins as described herein.
[0164] The scope of this invention also includes sequence variants of the claimed nucleic acids, proteins, antibodies, antibody fragments, and / or fusion proteins, such as those defined by sequence identity % that maintain similar binding properties to the present invention. Such variants exhibiting alternative sequences but maintaining substantially the same binding properties (such as target specificity) as the specific sequence provided are referred to as functional analogs or functionally similar. Sequence identity refers to the percentage of identical nucleotides or amino acids when sequence alignment is performed.
[0165] As used herein, “sequence identity” refers to the degree to which sequences are identical on a nucleotide-by-nucleotide or amino acid-by-amino acid basis within a comparison window. Therefore, the “sequence identity percentage” can be calculated by comparing two best-aligned sequences within a comparison window. This involves determining the number of positions in the two sequences where the same nucleic acid bases (e.g., A, T, C, G, I) or the same amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) occur to obtain the number of matching positions. The number of matching positions is then divided by the total number of positions in the comparison window (i.e., the window size), and the result is multiplied by 100 to obtain the sequence identity percentage. This includes nucleotides and polypeptides that have at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any reference sequence described herein, typically wherein the polypeptide variant maintains at least one biological activity of the reference polypeptide.
[0166] Those skilled in the art will understand that, due to the degeneracy of the genetic code, there are many nucleotide sequences encoding polypeptides as described herein. Some of these polynucleotides have very little homology or sequence identity with the nucleotide sequence of any natural gene. However, the present invention specifically considers polynucleotides that vary due to differences in codon usage. Deletions, substitutions, and other alterations in sequences belonging to the aforementioned sequence identity are also included in the present invention.
[0167] Protein sequence modifications that may occur through substitution are also included within the scope of this invention. As defined herein, substitution is a modification of the amino acid sequence of a protein, whereby one or more amino acids are replaced by the same number of (different) amino acids, thereby producing a protein containing an amino acid sequence different from the original protein. Substitution is preferably performed without significantly altering protein function. Similar to addition, substitution can be natural or artificial. It is well known in the art that amino acid substitutions can be performed without significantly altering protein function. This is especially true when the modification involves the substitution of “conserved” amino acids, i.e., replacing one amino acid with another amino acid with similar properties. Such “conserved” amino acids can be natural or synthetic and can be substituted without significantly affecting the structure and function of the protein due to differences in size, charge, polarity, and conformation. Typically, many amino acids can be substituted with conserved amino acids without adversely affecting protein function.
[0168] Generally, nonpolar amino acids Gly, Ala, Val, Ile, and Leu; nonpolar aromatic amino acids Phe, Trp, and Tyr; neutral polar amino acids Ser, Thr, Cys, Gln, Asn, and Met; positively charged amino acids Lys, Arg, and His; and negatively charged amino acids Asp and Glu represent groups of conserved amino acids. This list is not exhaustive. For example, it is well known that Ala, Gly, Ser, and sometimes Cys can be used interchangeably, even if they belong to different groups.
[0169] Substitution mutations cause the removal of at least one amino acid residue in a nucleic acid molecule and the insertion of a different residue.
[0170] Possible amino acid substitutions :
[0171]
[0172] Substantial modification of the biological properties of fusion proteins is achieved through selective substitution, which has significantly different effects on: (a) the structure of the polypeptide backbone in the substitution region, such as as a sheet or helical conformation; (b) the charge or hydrophobicity of the molecule at the target site; or (c) the bulk of the side chains.
[0173] Conservative amino acid substitutions are not limited to naturally occurring amino acids, but include synthetic amino acids. Commonly used synthetic amino acids are ω-amino acids of various chain lengths and cyclohexylalanine, which are neutral nonpolar analogs; citrulline and methionine sulfoxide, which are neutral nonpolar analogs; phenylglycine, which is an aromatic neutral analog; cysteine, which is a negatively charged analog; and ornithine, which is a positively charged amino acid analog. As with naturally occurring amino acids, this list is not exhaustive, but merely an example of substitutions known in the art.
[0174] In specific embodiments, the present invention considers cells genetically modified to express the fusion protein considered herein for use or prevention of autoimmune diseases, spasms, dystonia, hyperhidrosis and / or cosmetic medicine.
[0175] As used herein, the terms “genetic engineering” or “genetic modification” refer to the addition of additional genetic material in the form of DNA or RNA to the total genetic material of a cell. The terms “genetically modified cell,” “modified cell,” and “redirected cell” are used interchangeably.
[0176] As used herein, “antibody” generally refers to a protein consisting essentially of one or more polypeptides encoded by immunoglobulin genes or segments of immunoglobulin genes. The term “antibody segment” may also be considered when using the term “antibody.” Recognized immunoglobulin genes include the κ, λ, α, γ, δ, ε, and μ constant region genes, as well as a large number of immunoglobulin variable region genes. Light chains are classified as κ or λ. Heavy chains are classified as γ, μ, α, δ, or ε, defining the immunoglobulin classes IgG, IgM, IgA, IgD, and IgE, respectively. The basic immunoglobulin (antibody) structural unit is known to consist of a tetramer or dimer. Each tetramer consists of two pairs of identical polypeptide chains, each pair having a “light” (L) chain (approximately 25 kDa) and a “heavy” (H) chain (approximately 50–70 kDa). The N-terminus of each chain defines a variable region of approximately 100 to 110 or more amino acids, primarily responsible for antigen recognition. The terms “variable light chain” and “variable heavy chain” refer to these variable regions of the light and heavy chains, respectively.
[0177] In embodiments, the nucleic acid molecules of the present invention are intended to contain sequences encoding mammalian antibodies, particularly human antibodies. In embodiments, the nucleic acid molecules contain sequences or fragments thereof encoding antibodies.
[0178] "Autoantibodies" are antibodies produced by B cells that are specific to their own antigens.
[0179] "siRNA (small interfering RNA)" is a short double-stranded RNA molecule, typically 20-25 nucleotides in length, that promotes the degradation of complementary mRNA, leading to the silencing of specific genes through a process called RNA interference (RNAi).
[0180] "shRNA (short hairpin RNA)" is an RNA molecule that forms a stem-loop structure and is processed by the cell into siRNA-like fragments. It also induces gene silencing through RNA interference. When shRNA is expressed by a DNA construct integrated into the genome, it is typically used for sustained gene silencing.
[0181] In the context of this invention, siRNA and shRNA serve as key molecular tools for downregulating or silencing specific genes involved in neuromuscular signaling, particularly AChR and MuSK. When administered or delivered directly via suitable transfection vectors, siRNA molecules can target and degrade mRNA transcripts, thereby preventing the translation of AChR or MuSK proteins and effectively reducing the sensitivity of muscle cells to acetylcholine-induced excitation. The use of siRNA offers advantages in transient, dose-dependent gene silencing and reduced immune responses due to their short length and delivery via various vectors, such as lipid nanoparticles or adeno-associated viruses (AAVs). On the other hand, shRNA, through the integration of DNA constructs encoding shRNA sequences, is processed intracellularly into mature RNA molecules, providing a means for more durable gene silencing. These shRNA sequences can be expressed long-term, providing long-term therapeutic effects, which is advantageous for conditions requiring sustained inhibition of neuromuscular signaling, such as myasthenia gravis. Combining siRNA- and shRNA-based approaches with tissue-specific promoters ensures that silencing is localized to the desired cell type, reducing the risk of off-target effects and enhancing therapeutic specificity. Furthermore, combining RNA interference technology with nucleic acid-based therapies (such as therapies encoding modified receptors or neurotoxins) provides a new strategy for finely modulating neuromuscular function while minimizing systemic adverse effects.
[0182] As used herein, a "linker" or "spacer" refers to a short amino acid sequence that connects two or more protein domains or functional units within a single polypeptide chain. The primary function of a linker is to maintain the structural integrity and independent function of the fusion protein domains while preventing steric hindrance or unwanted interactions. Linkers can be classified as rigid or flexible. Rigid linkers (typically proline-rich) serve as structural spacers that minimize domain interference, while flexible linkers (typically G-rich) provide mobility and adaptability, facilitating proper folding and functional interactions. Glycine-serine (Gly-Ser or GS) linkers are among the most commonly used flexible linkers because they enhance protein stability in aqueous environments and provide the necessary spatial separation between domains. By optimizing the linker sequence, the structural and functional properties of fusion proteins can be modulated to ensure efficient expression, proper domain folding, and preserved biological activity. Non-limiting examples of linkers include glycine polymers, glycine-serine polymers, glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art, such as the Whitlow linker. Glycine and glycine-serine polymers are relatively unstructured and therefore can be used as neutral linkers between fusion protein domains as described herein. However, rigid linkers, cleavable linkers, affinity linkers, helical linkers, spiral coil linkers, or linkers with structural motifs may also be used, depending on the specific requirements of the fusion protein, including the desired distance and orientation between domains, the need for flexibility or rigidity, and any additional functionality that may be required.
[0183] In some embodiments, the nucleic acid molecule contains a sequence encoding an adapter. In some embodiments, the fusion protein contains an adapter. In further embodiments, the adapter is repeated.
[0184] By conjugating neurotoxins to receptors on the motor endplate, the resulting fusion protein can be selectively expressed on the motor endplate anchored via a linker sequence. This structural conformation ensures targeted localization and retention of the protein within the motor endplate, thereby facilitating its directed transport to the presynaptic membrane. This targeted delivery mechanism enhances the specificity of neurotoxin activity while minimizing off-target effects and systemic distribution.
[0185] Therefore, in one embodiment, the neurotoxin is coupled to the motor endplate receptor via a connector sequence. In another embodiment, BoNT or a fragment thereof is fused to AChR or a fragment thereof via a connector.
[0186] "Transfection" is the process of introducing nucleic acids, such as DNA or RNA, into eukaryotic cells to achieve the expression or silencing of specific genes. In the context of this invention, transfection plays a crucial role in the direct delivery of therapeutic nucleic acids (such as siRNA, shRNA, or plasmid DNA encoding modified receptors or BoNT or TeNT genes) to target cells (such as muscle or skin cells). By using transfection techniques well-known in the art, this invention enables precise modulation of gene expression at the neuromuscular junction, particularly by targeting the expression of receptors such as AChR and MuSK or silencing specific genes involved in neuromuscular transmission. This method allows for local and sustained expression of therapeutic proteins (including BoNT or TeNT) while minimizing systemic exposure and associated side effects. Depending on the target cell type and therapeutic goal, transfection can be achieved through a variety of methods, such as lipid nanoparticles (LNPs), polyethyleneimine (PEI) particles, viral vectors, or electroporation.
[0187] Medical conditions
[0188] Autoimmune diseases are illnesses in which the immune system mistakenly targets and attacks healthy tissues of the body, recognizing them as foreign invaders. These diseases are caused by a malfunction in the adaptive immune system and differ from autoinflammatory diseases associated with the innate immune system. More than 80 autoimmune diseases are known, and recent research suggests over 100 different types exist. These diseases can affect almost any part of the body, with symptoms ranging from general fatigue, low-grade fever, and malaise to more specific manifestations such as joint pain, rashes, and neurological disorders. The causes of autoimmune diseases are multifactorial, involving both genetic susceptibility and environmental triggers. Common autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, and psoriasis. Diagnosis is often complicated by the wide variation and fluctuating nature of symptoms. Treatment typically focuses on controlling symptoms and suppressing an overactive immune response, with options such as immunosuppressants, corticosteroids, and biologics. However, these treatments do not provide a cure; long-term management is usually required.
[0189] Myasthenia gravis (MG) is a chronic autoimmune disease characterized by skeletal muscle weakness due to impaired neuromuscular transmission. The pathophysiology of MG involves the production of antibodies that target and disrupt nicotinic acetylcholine receptors (AChRs) located at the neuromuscular junction (NMJ), leading to muscle weakness. The main antibodies in MG are immunoglobulins G1 (IgG1) and IgG3, which trigger complement-mediated damage or block AChR function, thereby preventing effective transmission between nerve and muscle cells. Additionally, antibodies against other proteins, such as muscle-specific kinase (MuSK), lipoprotein receptor-associated protein 4 (LRP4), and agrin, have been identified in certain subgroups of MG patients, contributing to the variability in disease presentation and severity. The thymus is often abnormal in MG patients, with some individuals developing thymomas or lymphoid hyperplasia. The clinical presentation of MG is highly variable, ranging from ocular symptoms (such as ptosis and diplopia) to generalized muscle weakness, which in severe cases may involve respiratory muscles and lead to respiratory failure. Diagnosis is supported by serological testing for specific antibodies, electromyography (EMG), and repetitive stimulation testing. Treatment strategies include acetylcholinesterase inhibitors to enhance neuromuscular transmission, immunosuppressive drugs to reduce autoimmune activity, thymectomy in selected cases, and interventions such as plasmapheresis during acute exacerbations. In rare cases, certain medications may trigger or worsen MG, including specific antibiotics and immune checkpoint inhibitors.
[0190] Spasticity is a movement disorder characterized by an abnormal increase in muscle tone, usually in response to passive stretching, caused by damage to the central nervous system (CNS). This condition involves an increased speed dependence on resistance to movement, often accompanied by reflex antiprogression. Spasticity is commonly associated with upper motor neuron syndromes such as cerebral palsy, multiple sclerosis, and spinal cord injury. Spasticity originates from an imbalance between excitatory and inhibitory signals to alpha motor neurons, leading to increased muscle excitability. This excessive muscle contraction disrupts coordinated movement, resulting in functional impairments such as reduced range of motion, contractures, and gait abnormalities. Treatment for spasticity aims to reduce muscle tone and improve motor function, with botulinum toxin type A (BoNT-A) playing a significant role in contemporary management. BoNT-A works by inhibiting the release of acetylcholine at the neuromuscular junction, reducing involuntary muscle activity. This chemical denervation provides symptom relief, particularly for focal spasticity, and can enhance joint range of motion and muscle function, although its benefits are often temporary and require repeated injections. While BoNT-A is effective, its use may be associated with side effects, including muscle weakness in the target and adjacent muscles. The optimal treatment window is typically within 4 to 6 weeks after injection, after which spasticity may recur. Therefore, BoNT-A remains a key intervention for managing spasticity, but its potential to cause muscle weakness must be carefully considered for effective treatment.
[0191] Dystonia is a neuromotor disorder characterized by persistent or repetitive muscle contractions resulting in twisting, abnormal postures, or involuntary movements. These symptoms can resemble tremors and typically worsen with physical activity, potentially spreading to adjacent muscles. The condition can be caused by a variety of factors, including genetic factors, infection, trauma, and drug reactions. Treatment for dystonia is tailored to individual needs and can involve oral medications, physical therapy, and surgical interventions such as deep brain stimulation. A key treatment modality is the chemical denervation via the injection of botulinum neurotoxin (BoNT), which effectively targets lesions and segmental dystonia. BoNT functions by blocking the release of acetylcholine, inhibiting muscle contraction in the affected area, thereby alleviating dystonia symptoms. In clinical settings, BoNT is considered a key therapeutic tool, particularly for focal dystonia, where a neurotoxin is injected into the target muscle group. Additionally, treatment may include oral anticholinergics, dopamine-based therapies for specific forms (such as dopa-responsive dystonia), and deep brain stimulation in severe, refractory cases.
[0192] Hyperhidrosis is a medical condition characterized by excessive sweating beyond what is needed to regulate body temperature. This abnormal sweating usually occurs without physical exertion or heat exposure and may affect specific areas of the body, such as the palms, soles, armpits, and face, or it may be widespread throughout the body. The condition is classified as primary (focal) hyperhidrosis and secondary hyperhidrosis. Primary hyperhidrosis is localized and often hereditary, while secondary hyperhidrosis is caused by underlying conditions such as endocrine disorders or medications. Diagnosis is usually clinical, with tests such as sweat tests helping to confirm the condition. Treatment strategies employed: For mild cases, topical antiperspirants and oral anticholinergics are used. For more severe cases, botulinum toxin injections (BTX-A) represent an effective and FDA-approved option. BTX-A works by cleaving the SNAP-25 protein, preventing the release of acetylcholine, which is responsible for stimulating sweat glands. Therefore, sweating is significantly reduced in the treated area for up to nine months, with continued efficacy requiring repeated treatments. Despite its high effectiveness, BTX-A is typically reserved for patients who do not respond to conservative treatments due to associated costs and the need for repeated injections. In addition to BTX-A, other interventions may be considered depending on the severity and location of hyperhidrosis, including iontophoresis, sympathectomy, and various surgical options.
[0193] As used in this article, "aesthetic medicine" refers to the branch of medical practice that focuses on enhancing appearance through minimally invasive or non-invasive procedures (often employing pharmacological, biological, or device-based interventions). It encompasses treatments that improve skin texture, volume loss, muscle activity, and overall facial and body aesthetics while maintaining the overall appearance of the body. BoNT (primarily serum type A) is a cornerstone because it induces temporary chemo-denervation by inhibiting the release of acetylcholine at the neuromuscular junction. BoNT is widely used to reduce dynamic wrinkles, including frown lines, forehead wrinkles, outer canthal wrinkles, perioral wrinkles, nasal wrinkles, and platysma wrinkles. In addition to facial rejuvenation, BoNT is also suitable for reducing masseter hypertrophy, hyperhidrosis, and other functional cosmetic concerns. Aesthetic medicine also integrates complementary forms such as dermal fillers for volume restoration, laser therapy for surface resurfacing, chemical peels for epidermal renewal, and energy-based devices for skin tightening. BoNT administration and other cosmetic treatments require precise dosing, targeted injection techniques, and personalized treatment plans to optimize safety and efficacy while minimizing complications such as ptosis, asymmetry, or unintended spread. Regulatory approvals (including FDA approval) define specific indications, while non-label use expands the scope of therapeutic applications. Combination therapies utilizing BoNT and other aesthetic interventions have demonstrated synergistic benefits.
[0194] In cosmetic medicine, BoNT refers to the clinical application of botulinum neurotoxin (primarily serum type A) to modulate facial muscle tissue and improve the appearance of dynamic wrinkles and other cosmetic concerns. BoNT works by inhibiting the release of acetylcholine at the neuromuscular junction, resulting in temporary muscle relaxation and reduced expression lines. BoNT-A is primarily approved for aesthetic indications such as frown lines, and its off-label applications extend to forehead wrinkles, outer canthal wrinkles (crow's feet), perioral wrinkles, nasal wrinkles (rabbit lines), shaping the jawline by reducing the masseter muscle, and platysma wrinkles in the neck. Administration techniques vary depending on anatomical location, muscle function, and patient-specific factors, requiring precise injection sites to avoid complications such as ptosis, asymmetry, or unintended muscle spread. Treatment efficacy is typically observed within days, peaking within two weeks, with results lasting approximately 3 to 4 months. BoNT-A is frequently used in conjunction with other cosmetic procedures, including dermal fillers for volume enhancement, laser resurfacing for texture improvement, and thread lifts for tissue repositioning. Although adverse effects are usually mild and transient, including local abrasions, swelling, and rare resistance due to antibody formation, appropriate patient selection and injection techniques minimize the risks.
[0195] Compositions and Formulations
[0196] The compositions considered herein may comprise one or more peptides, polynucleotides, carriers containing said polynucleotides, genetically modified immune effector cells, etc., as considered herein. The compositions include, but are not limited to, pharmaceutical compositions.
[0197] "Pharmaceutical composition" means a composition formulated in a pharmaceutically acceptable or physiologically acceptable solution for administration alone or in combination with one or more other therapeutic modalities to cells or animals. It should also be understood that, if desired, the compositions of the present invention can also be administered in combination with other agents, such as cytokines, growth factors, hormones, small molecules, chemotherapeutic agents, prodrugs, drugs, antibodies, or other various pharmaceutically active agents. There are practically no limitations on other components that may also be included in the composition, provided that the additional agents do not adversely affect the composition's ability to deliver the intended therapeutic effect.
[0198] The phrase “pharmaceutically acceptable” is used herein to refer to compounds, materials, compositions, and / or dosage forms that are suitable for use in human and animal tissue contact with reasonable medical judgment without excessive toxicity, irritation, allergic reactions or other problems or complications, and have a reasonable benefit / risk ratio.
[0199] As used herein, “pharmaceutically acceptable carriers, diluents, or excipients” include, but are not limited to, any adjuvant, carrier, excipient, gliding agent, sweetener, diluent, preservative, dye / coloring agent, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier that has been approved by the United States Food and Drug Administration for acceptable use in humans or livestock. Exemplary pharmaceutically acceptable carriers include, but are not limited to: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; tragali gum; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffin wax, silicone, bentonite, silicic acid, and zinc oxide; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginate; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffer solutions; and any other compatible substances used in pharmaceutical preparations.
[0200] In certain embodiments, the compositions of the present invention comprise an amount of CAAR-expressing immune effector cells as conceived herein. As used herein, the term “amount” refers to an “effective amount” or “effective dose” of genetically modified therapeutic cells, such as T cells, to achieve a beneficial or desired preventive or therapeutic outcome, including clinical efficacy.
[0201] "Prophylactic effective dose" refers to the amount of genetically modified therapeutic cells that effectively achieve the desired preventive outcome. Typically, but not always, the prophylactic effective dose is less than the therapeutic effective dose because the prophylactic dose is administered to the subject before or in an early stage of the disease. The term "prophylaxis" does not necessarily refer to complete suppression or prevention of a specific medical condition. Prophylaxis also refers to reducing the risk of developing a medical condition or worsening its symptoms.
[0202] The "therapeutic effective amount" of genetically modified therapeutic cells can vary depending on factors such as an individual's disease state, age, sex, weight, and the ability of stem cells and progenitor cells to elicit the desired response in an individual. Therapeutic effective amount is also the amount in which the beneficial therapeutic effect outweighs any toxic or harmful effects of the virus or transduced therapeutic cells. The term "therapeutic effective amount" includes the amount that effectively "treats" a subject (e.g., a patient). When indicating a therapeutic amount, the precise amount of the composition of the invention to be administered can be determined by a physician taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition.
[0203] Typically, compositions comprising activated and expanded cells as described herein can be used to treat and prevent diseases such as autoimmune disorders, spasms, dystonia, hyperhidrosis, and / or cosmetic medicine. The genetically modified cells of the present invention can be administered alone or as pharmaceutical compositions in combination with carriers, diluents, and / or excipients. In certain embodiments, the pharmaceutical compositions contemplated herein comprise a quantity of genetically modified cells and one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients.
[0204] The pharmaceutical compositions of the present invention, comprising genetically modified cells according to the present invention, may contain buffers, such as neutral buffered salt solutions, phosphate buffered salt solutions, etc.; carbohydrates, such as glucose, mannose, sucrose, or dextran, mannitol; proteins; polypeptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of the present invention are preferably formulated for parenteral administration, such as intravascular (intravenous or intra-arterial), intraperitoneal, or intramuscular administration.
[0205] Liquid pharmaceutical compositions, whether solutions, suspensions, or other similar dosage forms, may contain one or more of the following: a sterile diluent, such as water for injection, saline solution (preferably physiological saline), Ringer's solution, isotonic sodium chloride; a fixing oil, such as synthetic monoglycerides or diglycerides, polyethylene glycol, glycerol, propylene glycol, or other solvents that can be used as a solvent or suspension medium; an antibacterial agent, such as benzyl alcohol or methylparaben; an antioxidant, such as ascorbic acid or sodium bisulfite; a chelating agent, such as ethylenediaminetetraacetic acid; a buffer, such as acetate, citrate, or phosphate; and a reagent for adjusting osmotic pressure, such as sodium chloride or dextran. Parenteral preparations may be packaged in ampoules, disposable syringes, or multi-dose vials made of glass or plastic. Injectable pharmaceutical compositions are preferably sterile.
[0206] Treatment
[0207] As used herein, the terms "individual" and "subject" are generally used interchangeably and refer to any animal exhibiting symptoms of a disease, disorder, or condition that can be treated with gene therapy vectors, cell-based therapeutic agents, and methods disclosed elsewhere herein. In a preferred embodiment, a subject includes any animal exhibiting symptoms of a disease, disorder, or condition of the hematopoietic system (e.g., an autoimmune disease) that can be treated with cell-based therapeutic agents and methods disclosed herein. Suitable subjects include humans, laboratory animals (e.g., mice, rats, rabbits, or guinea pigs), farm animals, and domestic animals or pets (e.g., cats or dogs). Non-human primates are included, preferably human patients.
[0208] As used herein, “treatment” or “treating” includes any beneficial or desired effect on the symptoms or pathology of a disease or condition, and may even include a minimum reduction in one or more measurable markers of the disease or condition being treated. Treatment may optionally involve the reduction or relief of symptoms of a disease or condition, or the slowing of its progression. “Treatment” does not necessarily mean the complete eradication or cure of a disease or condition or its associated symptoms.
[0209] As used herein, "prevention" and similar terms such as "prevented," "preventive," or "preventative" refer to methods of preventing, suppressing, or reducing the likelihood of the occurrence or recurrence of a disease or condition. It also refers to delaying the onset or recurrence of a disease or condition, or delaying the onset or recurrence of its symptoms. As used herein, "prevention" and similar terms also include reducing the intensity, effect, symptoms, and / or burden of a disease or condition before its onset or recurrence.
[0210] The dosage and frequency of administration will be determined by factors such as the patient's condition and the type and severity of the disease, but clinical trials can determine the appropriate dosage.
[0211] The compositions considered herein can be administered in any convenient manner, including via aerosol inhalation, injection, ingestion, infusion, implantation, or transplantation. In a preferred embodiment, the compositions are administered parenterally. As used herein, the phrases “parenterical administration” and “prescription” refer to a mode of administration other than enteral and local administration, typically by injection, and including but not limited to intravascular, intravenous, intramuscular, intra-arterial, intrathecal, intracapsular, intra-bursal, intraorbital, intratumoral, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intraspinal, and intrasternal injections and infusions.
[0212] General Instructions
[0213] Unless the context suggests otherwise, all words and terms used herein shall have the same meaning as commonly given to them by those skilled in the art. All terms used in the singular shall include the plural form of the term, and vice versa.
[0214] It should be understood that the specific embodiments described herein are shown by way of illustration and not as limitations on the invention. The main features of the invention may be employed in various embodiments without departing from the scope of the invention. Using the most conventional study, those skilled in the art will recognize or be able to identify many equivalents of the specific procedures described herein. Such equivalents are considered to be within the scope of the invention and are covered by the claims. All publications and patent applications referenced in the specification indicate the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are incorporated herein by reference and have the same effect as each individual publication or patent application specifically and individually indicated as incorporated by reference.
[0215] When used in conjunction with the term "comprising," the words "a" or "an" in the claims and / or description may mean "one," but it is also consistent with the meanings of "one or more," "at least one," and "one or more." The term "or" in the claims is used to mean "and / or" unless explicitly stated otherwise, referring only to alternatives or where the alternatives are mutually exclusive. However, this disclosure supports only the definitions of alternatives and "and / or." Throughout this application, where applicable, the term "about" indicates a value including inherent error variations in the device used to determine values or variations between study subjects. Attached Figure Description
[0216] The invention is illustrated by way of example in the following figures. The figures provide further description of potential preferred embodiments to enhance support for one or more non-limiting embodiments of the invention.
[0217] Description of the attached diagram:
[0218] Figure 1 Example plasmid map of AChR-BoNT fusion protein.
[0219] Figure 2 Detailed view of the plasmid map of the AChR BoNT fusion protein with a quadruple GGGGS linker.
[0220] Figure 3 Detailed view of the plasmid map of the AChR BoNT fusion protein with an 8x GGGGS linker.
[0221] Figure 4 : A partial plasmid map of the AChR BoNT fusion protein with a five-fold repeat sequence of the human IgG hinge region as a linker.
[0222] Figure 5 : Schematic diagram of an example of a MuSK protein modified with a haploid repeat of an Ig-like domain and a fusion protein (left) and an example of a normal (wild-type) MuSK (right).
[0223] Figure 6 Example plasmid maps of constructs containing mouse AChR and control shRNA, as well as chimeric human AChR and MYOG promoters.
[0224] Figure 7 Example plasmid maps of mouse AChR and U6 promoters with only one shRNA and a luciferase construct serving as a reporter gene.
[0225] Example
[0226] The present invention is illustrated by the following disclosed embodiments. These embodiments provide technical support and a more detailed description of potentially preferred, non-limiting implementations of the invention.
[0227] Implementation Examples Overview
[0228] To demonstrate the functionality and beneficial properties of the nucleic acid molecules and fusion proteins described herein, the following examples should be considered:
[0229] - RNA interference (RNAi)-mediated downregulation of acetylcholine receptors (AChR) in muscle cells
[0230] - Engineering modification of AChR for controlled BoNT expression at the motion endplate
[0231] Example 1: RNA interference (RNAi)-mediated downregulation of acetylcholine receptors (AChR) in muscle cells
[0232] For RNA interference (RNAi)-mediated downregulation of acetylcholine receptors (AChR) in muscle cells, two main methods are used: direct injection of siRNA or transfection with a vector encoding shRNA.
[0233] In the case of siRNA administration, unpackaged siRNA is injected directly into muscle tissue. However, cellular uptake is significantly enhanced by appropriate delivery carriers (e.g., liposomes, lipid nanoparticles (LNPs), polyethyleneimine (PEI), or similar transfection agents).
[0234] Using vectors encoding shRNA provides an extended RNAi effect, ensuring sustained downregulation of AChR throughout the extended timeframe. This is further optimized by selecting appropriate promoters or incorporating scaffold / matrix attachment region (S / MAR) elements. In experimental applications, four different shRNA constructs were used, each individually bound to a plasmid vector containing a combination of the U6 promoter or miR30 precursor with a cytomegalovirus (CMV) promoter or a muscle-specific MYOG promoter.
[0235] Furthermore, gene constructs containing shRNA expression cassettes are co-integrated with other genetic elements, allowing for the simultaneous expression of modified AChR sequences resistant to RNAi-mediated degradation. Specifically, the modified AChR gene sequences are designed to include target sites for shRNA binding, making them immune to endogenous shRNA-mediated knockdown. Such modifications should preferably avoid transmembrane domains, as alterations in this region can disrupt the targeted integration and functional localization of AChRs at the neuromuscular endplate.
[0236] For sequence modification, heterologous gene sequences from other species are used as templates, where chimeric sequences incorporate species-specific variations into the shRNA target region. For example, a chimeric AChR sequence is inserted into a plasmid containing the MYOG promoter and three shRNAs, each embedded in the miR30 precursor. This chimeric sequence incorporates a rabbit AChR amino acid sequence fragment at the shRNA target site, which differs from the human and mouse AChR sequences. The shRNA construct is specifically designed to target mouse AChR, ensuring that endogenous mouse AChR is downregulated in transfected mouse muscle cells, while the resistant chimeric receptor is effectively expressed, facilitating experimental validation in in vivo models.
[0237] Example 2: Engineered AchR for controlled BoNT expression at the motion endplate
[0238] To prevent accidental release of BoNTs, proteins can fuse to transmembrane domains via adaptor sequences. However, the ubiquitous expression of BoNTs across the cell membrane presents two significant drawbacks. First, BoNT proteins arrayed on the membrane surface can trigger immunogenic responses, potentially leading to the formation of neutralizing antibodies. Second, despite membrane anchoring, there remains a risk of eventual BoNT release, which can impair targeted therapy efficacy and increase off-target effects.
[0239] To avoid these problems, this invention employs a strategy of specifically expressing BoNT at the neuromuscular junction (NMJ) by fully utilizing a variant of the ε subunit of the acetylcholine receptor. In the initial experimental approach, an engineered DNA plasmid was created in which the ε subunit of the AChR was fused at the C-terminus to a sequence encoding BoNT via a GGGGS linker. This construct was then used to transfect mouse tibialis muscle, resulting in an observable decrease in muscle tone. However, the observed phenotypic effect did not perfectly align with the expected BoNT-induced paralysis, indicating that the BoNT fusion protein was not the cause of the observed results.
[0240] Further analysis revealed that the synaptic cleft width (10-40 nm) may be too large to allow BoNT fusion proteins to effectively reach presynaptic nerve endings and exert their intended pharmacological effects. This finding sparked a novel approach: achieving therapeutic effects by modifying AChR itself, rather than solely relying on BoNT-mediated neurotoxicity. This approach represents a paradigm shift in neuromuscular modulation, where engineered AChR variants can be used to achieve targeted pharmacological outcomes at the motor endplate, thereby minimizing systemic side effects and enhancing therapeutic precision.
[0241] References
[0242] 1. K. Kigasawa, K. Kajimoto, S. Hama, A. Saito, K. Kanamura, K. Kogure, Noninvasive delivery of siRNA into the epidermis by iontophoresis using anatopic dermatitis-like model rat, International Journal of Pharmaceutics, Volume 383, Issues 1–2, 2010
[0243] 2. Mahadi Hasan, Tatsuya Fukuta, Shinya Inoue, Hinako Mori, Mayuko Kagawa, Kentaro Kogure, Iontophoresis-mediated direct delivery of nucleic acid therapeutics, without use of carriers, to internal organs via non-blood circulatory pathways, Journal of Controlled Release, Volume 343, 2022
[0244] 3. Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. HumGene Ther. 1993 Apr;4(2):151-9. doi: 10.1089 / hum.1993.4.2-151. PMID: 8494924.
[0245] 4. Danko I, Wolff JA. Direct gene transfer into muscle. Vaccine. 1994 Dec;12(16):1499-502. doi: 10.1016 / 0264-410x(94)90072-8. PMID: 7879413.
Claims
1. A nucleic acid molecule for regulating neuromuscular transmission, said nucleic acid molecule comprising a sequence encoding one or more receptors or fragments thereof for a motor endplate.
2. The nucleic acid molecule of claim 1, wherein, The receptor of the motor endplate is an acetylcholine receptor (AChR), preferably a nicotinic acetylcholine receptor (nAChR) or a fragment thereof.
3. The nucleic acid molecule of claim 1 or 2, wherein, The receptor of the motor endplate comprises at least one subunit of the acetylcholine receptor (AChR), preferably an α, β, γ, δ and / or ε subunit, more preferably an ε subunit.
4. The nucleic acid molecule of claim 1, wherein, The receptors of the motor endplate are muscle-specific receptor tyrosine kinase (MuSK) and / or glutamate receptors or fragments thereof.
5. The nucleic acid molecule of claim 1, wherein, The nucleic acid molecule is either DNA or RNA.
6. The nucleic acid molecule of claim 5, wherein, The nucleic acid molecule contains a sequence encoding a neurotoxin.
7. The nucleic acid molecule of claim 6, wherein, The neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin.
8. The nucleic acid molecule of claim 1, wherein, The nucleic acid molecule contains a sequence encoding an antibody.
9. The nucleic acid molecule of claim 1, wherein, The nucleic acid molecule contains a sequence encoding siRNA and / or shRNA.
10. The nucleic acid molecule of claim 1, wherein, The nucleic acid molecule contains a sequence that encodes a linker.
11. A nucleic acid vector comprising the nucleic acid molecule according to claims 1-10, wherein, The vector is a viral vector, such as a lentiviral vector or a retroviral vector, a transposon, an RNA vector, or a nanoparticle, such as a lipid nanoparticle, a liposome, or polyethyleneimine (PEI).
12. A fusion protein, preferably comprising one or more of the features of any one or more of the preceding claims, said fusion protein comprising: a. The receptors and / or fragments thereof of the motor endplate, wherein, The receptors of the motor endplate are acetylcholine receptors (AChR), muscle-specific receptor tyrosine kinases (MuSK), and / or glutamate receptors and / or fragments thereof, and / or b. Neurotoxins, wherein the neurotoxin is botulinum toxin (BoNT) and / or tetanus toxin, and / or c. siRNA or shRNA.
13. An in vitro method for modulating neuromuscular transmission, said in vitro method comprising transfecting eukaryotic cells with a nucleic acid molecule according to any one of claims 1-10.
14. The in vitro method according to claim 13, wherein, The eukaryotic cells are skeletal muscle cells, smooth muscle cells, and / or skin cells.
15. A genetically modified cell comprising a nucleic acid molecule according to claims 1-10, a vector according to claim 11, or a fusion protein according to claim 12.
16. The genetically modified cell according to claim 15, wherein, The cells are eukaryotic cells selected from the group consisting of skeletal muscle cells, smooth muscle cells, or skin cells.
17. Use of the genetically modified cells according to claims 15-16 in the treatment or prevention of autoimmune diseases, spasms, dystonia, hyperhidrosis, myasthenia gravis, and / or cosmetic medicine.
Citation Information
Patent Citations
Nucleic acid-based botulinum neurotoxin for therapeutic use
US11707510B2
Methods for delivering siRNA via Ionthophoresis
US20110038937A1
